Athira Pharma has dosed the first subject in the Phase I clinical trial of its treatment candidate, ATH-1020, to potentially treat neuropsychiatric conditions.

An orally available, brain-penetrant small molecule, ATH-1020 is created to boost HGF/MET system. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The first-in-human placebo-controlled, randomised, double-blind, two-part trial will assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy subjects.

It will enrol nearly 68 subjects aged 18 to 85 years.

Part A or the single ascending dose (SAD) portion will assess up to four dose levels of ATH 1020.

In Part B or the multiple ascending dose (MAD) portion, up to three dose levels of ATH-1020 will be evaluated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of the trial is to analyse the safety and tolerability of the molecule.

According to the preclinical findings, ATH-1020 could lower depression-like behaviours and rescue mismatch negativity response.

These are translatable measures of event-linked potential that demonstrates steady and strong deficits in rodent models and patients with schizophrenia.

Athira Pharma president and CEO Mark Litton said: “Our novel approach targeting HGF/MET and ATH-1020’s unique pharmacology and mechanism of action, may be particularly well suited for potential treatment of neuropsychiatric indications, as evidenced by the compelling preclinical data we have recently presented. 

“We anticipate that the safety, tolerability and pharmacokinetic data from this Phase I study will help inform our further assessment of the potential of ATH-1020 in future clinical indications.”

In October last year, the company concluded subject enrolment in a placebo-controlled, randomised, Phase II ACT-AD trial of its small molecule, ATH-1017, in mild-to-moderate Alzheimer’s disease patients. 

It enrolled 77 patients at 14 trial centres in the US and Australia.